ClinicalTrials.gg
WithdrawnNCT06068140Updated Jul 11, 2024

Evaluation of the Effectiveness of the Complex of Carnitine Orotate and Biphenyl Dimethyl Dicarboxylate in the Adjuvant Therapy of Chronic Hepatitis D in Real Clinical Practice: a Prospective Cohort Study

An observational study in Chronic Viral Hepatitis B With Delta-Agent, sponsored by Kazakh Association of Internal Medicine Specialists. Withdrawn at 7 sites in Kazakhstan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Kazakh Association of Internal Medicine Specialists · Observational

Why this study was withdrawn
Administartive issues
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this observational study is to evaluate the effectiveness of the carnitine-orotate complex and biphenyl dimethyl dicarboxylate in the adjuvant therapy of chronic hepatitis D in real clinical practice: a prospective cohort study

02

Conditions studied

  • Chronic Viral Hepatitis B With Delta-Agent

Browse trials for

03

In context

Hepatitis B

1,045 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Lead sponsor

Kazakh Association of Internal Medicine Specialists is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Persons aged ≥18 to 75 years inclusive with a diagnosis of chronic hepatitis D who are undergoing outpatient monitoring at the place of residence.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes aged 18 to 75 years who are citizens of the Republic of Kazakhstan;
  • An established diagnosis of CGD (chronic viral with the delta agent);
  • Patients who have to taking peg-INF-alpha2a and/or have failed treatment with peg-INF-alpha2a;
  • Compensated liver disease ≤ CPT A (6 points);
  • Patients without severe concomitant diseases;
  • Patients who do not receive other therapy (metabolic therapy drugs, essential phospholipids, ursodeoxycholic acid, glycyrrhizic acid, ademetionine and others);
  • Patients who voluntarily signed the form.

Exclusion criteria

Exclusion Criteria:

  • Patients taking COC for more than 4 weeks before inclusion in the study;
  • Patients with to the COC;
  • Decompensated liver disease severity class > CPT A6;
  • Patients taking peg-IFN-alpha 2a;
  • Alcohol abuse according to the AUDIT-c questionnaire;
  • Pregnancy and lactation;
  • Patients with coinfection with , ;
  • ≤ 15 ml/min/1.73 m2;
  • Exclude patients with significant biochemical activity (, AST more than 10 ) and total more than 2 norms;
  • Patients with other causes of liver damage;
  • Drug addict people;
  • Malignant formations of the liver and other organs (in history and currently) or a increase in alpha-fetoprotein more than 5 times or more;
  • Patient takes part in an interventional clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Study Cohort

    Patients taking Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate

  • Control cohort

    Patients who do not take Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate

06

What researchers measure

Primary outcomes

  1. 1. Normalization of ALT levels during adjuvant CGD therapy at 12 months among study participants taking and not taking COC and BDD

    Time frame: at 12 months

Secondary outcomes

  1. Normalization of ALT levels during adjuvant CGD therapy at 6 months among study participants taking and not taking COCs AND BDD

    Time frame: at 6 months

  2. Dynamics of the level of fibrosis during adjuvant CGD therapy at 6 and 12 months among study participants taking and not taking COCs AND BDD

    Time frame: at 6 and 12 months

  3. Viral load during adjuvant CGD therapy at 6 and 12 months among study participants taking and not taking COC and BDD

    Time frame: at 6 and 12 months

  4. Adherence to COC and BDD therapy against the background of adjuvant CGD therapy among study participants taking and not taking COCs and BDD

    Time frame: up to 12 months since enrollment

  5. Dynamics of changes in the total score of the quality of life questionnaire

    Time frame: up to 12 months since enrollment

  6. Incidence of adverse and serious unexpected adverse reactions associated with the use of COC and BDD

    Time frame: up to 12 months since enrollment

  7. Satisfaction of patients with CGD with combination therapy of COCs and BDD

    Time frame: up to 12 months since enrollment

07

Study locations

7 sites
  • State-owned public enterprise with the right of economic management "Enbekshikazakh Interdistrict Multidisciplinary Hospital"
    Esik, Almaty Region, Kazakhstan
  • Karasai interdistrict multidisciplinary hospital
    Kaskelen, Almaty Region, Kazakhstan
  • State-owned public enterprise with the right of economic management Regional infectious hospital of the state institution "Healthcare Department of the Almaty region"
    Taldykorgan, Zhetisu Region, Kazakhstan
  • LLP "InkarMed"
    Aktobe, Kazakhstan
  • Hepatology center on the basis of the State Public Enterprise at the RV "City Clinic No. 5"
    Almaty, Kazakhstan
  • Medical Center "iClinic"
    Astana, Kazakhstan
  • State-owned public enterprise with the right of economic management "Regional Clinical Hospital" of the Department of Public Health of the Turkestan region
    Turkestan, Kazakhstan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06068140
Lead sponsor
Kazakh Association of Internal Medicine Specialists
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Dec 2023 (estimated)
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Jul 11, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion